Suoh Maito, Tamori Akihiro, Amano-Teranishi Yuga, Nakai Takashi, Enomoto Masaru, Kawasaki Yasuko, Kioka Kiyohide, Kawada Norifumi
Department of Hepatology, Osaka City General Hospital, Japan.
Department of Hepatology, Osaka City University Graduate School of Medicine, Japan.
Intern Med. 2020;59(2):205-210. doi: 10.2169/internalmedicine.3504-19. Epub 2020 Jan 15.
The appropriate management of hepatitis B virus (HBV) infection during pregnancy has not been established in Japan. We herein report five HBV-infected pregnant Japanese women who received tenofovir disoproxil fumarate (TDF). Two of them had been born after the introduction of nationwide immunoprophylaxis and were vertically infected with HBV, highlighting the need to address mother-to-child transmission further. In both entecavir-experienced and nucleoside/nucleotide analog-naïve mothers, TDF suppressed HBV replication without serious adverse events. All five children were free from congenital disorders, growth impairment, and HBV infection. TDF showed safety and efficacy for pregnant woman with chronic hepatitis B and might have helped prevent mother-to-child transmission.
在日本,孕期乙型肝炎病毒(HBV)感染的恰当管理方法尚未确立。我们在此报告5名感染HBV的日本孕妇接受替诺福韦酯(TDF)治疗的情况。其中2名孕妇在全国性免疫预防措施实施后出生,且母婴垂直感染HBV,这凸显了进一步解决母婴传播问题的必要性。在既往使用过恩替卡韦以及初治的母亲中,TDF均能抑制HBV复制,且未发生严重不良事件。所有5名儿童均未出现先天性疾病、生长发育障碍及HBV感染。TDF对慢性乙型肝炎孕妇显示出安全性和有效性,可能有助于预防母婴传播。